Fig 1.
Flowchart depicting the selection of the study population.
Table 1.
Clinical characteristics of reports with finasteride as the primary suspected drug from the FAERS database.
Fig 2.
Basic information and patient characteristics according to the report.
(A) The annual distribution of finasteride administration related AEs reports from 2004 to April 2024. (B) Country distribution of AEs for finasteride administration, brighter colors represent a higher number of reports, Map created in R using mapdata package (https://cran.r-project.org/web/packages/mapdata/index.html) and the FAERS database (https://open.fda.gov/data/downloads/). (C) Sex ratio of male and female in reported events. (D) Occupational information ratio in reported events. (E) Age distribution ratio in reported events. (F) Ratio of indications in reported events. (G) Ratio of outcomes in reported events. Visualization through proportional area map, larger areas represent more reporters.
Fig 3.
Signal strength of reports of finasteride administration at the SOC level.
Table 2.
Signal strength of reports of finasteride administration at the preferred term level in the FAERS database.
Fig 4.
Time to onset of AEs in male and female patients receiving finasteride therapy.
AEs: adverse events.
Fig 5.
Sex-differentiated risk signal volcano plot for finasteride.